TIKOSYN (Generic: Dofetilide) is a CARDIAC drug which went OFF PATENT on 09 October 2018 and the drug molecule, TIKOSYN is owned by Pfizer.
Upon approval of Dofetilide ANDA, the company will join the exclusive club of other 4 Generic Manufacturers (Sun, Greenstone, Bion, Mayne/Sigma).
The size of the market is over USD 200 Million (Rs 1,400 crore approximately). The Company has completed all data filings and up to date in GDUFA fee payments for 2019 and is waiting for approval from US FDA for commercial launch of the product.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app